VARIVAX Drug Profile

Summary for Tradename: VARIVAX

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for VARIVAX

Recent Clinical Trials for VARIVAX

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
AstraZeneca	Phase 4

See all VARIVAX clinical trials

Pharmacology for VARIVAX

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Live Attenuated Herpes Zoster Virus Vaccine Live Attenuated Varicella Zoster Virus Vaccine
Chemical Structure	Chickenpox Vaccine Herpes Zoster Vaccine Vaccines, Attenuated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for VARIVAX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for VARIVAX Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for VARIVAX Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	VARIVAX	varicella virus vaccine live	For Injection	103552	6,248,363	2019-11-23	Patent claims search
Merck Sharp & Dohme Llc	VARIVAX	varicella virus vaccine live	For Injection	103552	6,309,663	2019-08-17	Patent claims search
Merck Sharp & Dohme Llc	VARIVAX	varicella virus vaccine live	For Injection	103552	6,720,001	2019-10-18	Patent claims search

Market Dynamics and Financial Trajectory for VARIVAX

Last updated: April 10, 2026

What is VARIVAX and how does it fit into the current vaccine market?

VARIVAX is a live attenuated vaccine used for active immunization against varicella-zoster virus, responsible for chickenpox. Introduced by Merck & Co., its primary indication is in preventing chickenpox in children and susceptible adults. The vaccine became available in 1995 in the U.S.

The global varicella vaccine market is evolving with increased adoption driven by pediatric immunization programs, adult vaccination initiatives, and the introduction of combination vaccines. As of 2022, the market size was approximately USD 1.5 billion, projected to grow at a CAGR of 7% through 2027[1].

How does VARIVAX influence market share within the vaccine industry?

VARIVAX holds a dominant position in the live varicella vaccine segment, capturing around 80% of the global market share. It competes primarily with Varivax-L, a newer formulation, and emerging combination vaccines incorporating varicella. Despite these competitors, VARIVAX’s longstanding approval, proven efficacy, and established manufacturing competencies sustain its market dominance.

Key factors influencing its market share include:

• Brand recognition and trust: Decades of clinical data support its safety and effectiveness.
• Manufacturing capacity: Merck’s extensive production capabilities meet global demand.
• Pricing strategies: Competitive pricing remains critical, especially in developing markets.

However, patent expirations or biosimilar entries could threaten ongoing dominance; currently, VARIVAX remains under patent protection until at least 2030[2].

What are the primary drivers shaping VARIVAX’s financial trajectory?

The financial trajectory depends on multiple factors:

Growth drivers:

• Expansion in vaccination programs: Increasing adoption in emerging markets (e.g., China, India) boosts volume sales.
• Catch-up immunization initiatives: Targeting unvaccinated adults increases overall demand.
• Development of combination vaccines: Co-formulations including varicella components streamline immunization schedules.

Constraints:

• Market saturation: High coverage in developed countries limits growth.
• Regulatory barriers: Variations in approval processes across countries impact market access.
• Pricing pressures: Particularly in public sector markets, influence profitability.

Revenue trends:

Between 2017 and 2022, VARIVAX sales grew at a CAGR of 5%, reaching USD 1.2 billion in 2022[3]. Forecasts project steady growth to USD 1.8 billion by 2027, contingent upon successful market penetration and vaccine uptake. The growth rate may slow in mature markets but accelerate in regions with expanding immunization policies.

How are regulatory and competitive factors influencing future market potential?

Regulatory frameworks in key markets directly shape VARIVAX’s prospects:

• United States: Approval by the FDA since 1995; ongoing post-marketing surveillance supports market stability.
• Europe: EMEA approval achieved in 1996; newer guidelines favor combination vaccines.
• Asia: Rapid approval processes facilitate market expansion, especially in Japan, China, and India.

Biosimilar and vaccine innovator entries present long-term challenges:

• Biosimilars: No biosimilar versions currently available for VARIVAX due to vaccine classification but potential emergence as patent protections expire[4].
• Next-generation vaccines: Recombinant or subunit vaccines could displace live attenuated formulations if proven more effective or safer.

What are the strategic considerations for stakeholders?

• Manufacturers: Invest in expanding manufacturing capacity and pipeline development of combination vaccines.
• Buyers/Public Health Agencies: Leverage bulk purchasing and negotiate pricing to increase vaccination coverage.
• Investors: Monitor patent expiry timelines and pipeline innovations for valuation adjustments.

Summary of financial outlook

Year	Projected Revenue (USD billions)	CAGR	Key Factors
2022	1.2	5%	Mature market saturation, steady growth
2027	1.8	7%	Market expansion, new markets, combo vaccines

Key Takeaways

• VARIVAX maintains a dominant position in the live varicella vaccine market, supported by longstanding efficacy and manufacturing capacity.
• Global adoption, particularly in emerging markets, underpins steady revenue growth.
• Its future financial success hinges on market expansion, regulatory approvals, and potential biosimilar competition post-patent expiration.
• Strategic investments in combination vaccine development and regional marketing will influence long-term trajectory.
• Market saturation in developed regions presents growth limitations but opens opportunities in underserved markets.

FAQs

1. When does VARIVAX patent protection expire?
Patent protections for VARIVAX are slated to expire around 2030, after which biosimilar competition may emerge.

2. What are the main competitors to VARIVAX?
Currently, few direct biosimilar competitors exist. The primary competition comes from combination vaccines incorporating varicella components and emerging recombinant platforms.

3. How is the global vaccination policy affecting VARIVAX sales?
Expanded immunization programs in Asia, Latin America, and parts of Africa increase demand. Conversely, high coverage in developed countries limits growth.

4. Are there newer vaccines that could replace VARIVAX?
Yes. Recombinant subunit or DNA-based varicella vaccines under development could threaten live attenuated formulations if they demonstrate superior safety or efficacy.

5. What impact do regulatory changes have on VARIVAX’s market?
Approval processes and vaccination guidelines directly impact market access and adoption rates globally.

---

References:

[1] MarketWatch. (2022). Global varicella vaccine market forecast.
[2] U.S. Patent and Trademark Office. (2023). Patent database analysis.
[3] Merck Annual Report. (2022). Revenue and sales figures.
[4] World Health Organization. (2022). Vaccine policy updates.